Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Gastroenterology. 2008 Feb 13;134(5):1360–1368. doi: 10.1053/j.gastro.2008.02.014

Table 3.

Overview of Safety Data

Safety parameter (number of patients with AE) Terlipressin (n = 56) n (%) Placebo (n = 55) n (%)
AEs up to 7 days posttreatment
 All 52 (92.9) 49 (89.1)
 Related 18 (32.1) 12 (21.8)
Serious AEs up to 30 days posttreatment
 All 37 (66.1) 36 (65.5)
 Related 5 (8.9) 1 (1.8)
Deaths up to 30 days posttreatment
 All 27 (48.2) 27 (49.1)
 Related 0 (0.0) 0 (0.0)
Withdrawals because of AEs up to 7 days
 All 3 (5.4) 2 (3.6)
 Related 3 (5.4) 0 (0.0)

AEs, adverse events.